Text Size

Exercise, Oxidative Stress and HIV

This study has been completed.
Sponsor:
Information provided by:
Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier:
NCT00950937
First received: February 16, 2009
Last updated: August 4, 2009
Last verified: August 2009
History of Changes
  Purpose

The purpose of this study is to compare oxidative stress markers and the immunologic characteristics of HIV-infected and non-HIV subjects during a bout of moderate aerobic exercise followed by resistance exercises


Condition
HIV Infections

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Case-control Study to Test the Effects of a Bout of Aerobic Exercise Followed by Resistance Training on Antioxidant System in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV Subjects

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hospital de Clinicas de Porto Alegre:

Primary Outcome Measures:
  • Total Glutathione [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Catalase Activity [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ] [ Designated as safety issue: Yes ]
  • Glutathione S-transferase (GST) [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ] [ Designated as safety issue: Yes ]
  • Lipid Peroxidation [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ] [ Designated as safety issue: Yes ]
  • T CD4 [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ] [ Designated as safety issue: Yes ]
  • Neutrophil Count [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ] [ Designated as safety issue: Yes ]
  • Peak Oxygen Uptake [ Time Frame: 1 time, before the exercise protocol ] [ Designated as safety issue: Yes ]

Enrollment: 28
Study Start Date: June 2006
Study Completion Date: July 2008
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts
HIV Group
HIV infected persons
Control Group
Non HIV-infected persons

  Eligibility

Ages Eligible for Study:   20 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The participants of the HIV group were recruited at the outpatient HIV/AIDS care unit of the Hospital de Clínicas de Porto Alegre (HCPA), whereas the control group (non-HIV) was formed by volunteers of the city of Porto Alegre, Rio Grande do Sul, Brazil

Criteria

Inclusion Criteria:

  • HIV Group:without contraindications for exercise training; to highly active antiretroviral therapy (HAART) for at least 6 months before enrollment; be classified as low level of physical activity by international physical activity questionnaire (IPAQ) and did not use antioxidant supplements.
  • Control Group:negative result for HIV-1 test and the other criteria described above

Exclusion Criteria:

  • Subjects with previous history of cardiovascular and neurological disease, diabetes, dyslipidemia, tobacco using, physical disability and pregnant women were excluded from the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00950937

Locations
Brazil
Outpatient HIV/AIDS care unit of the Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
Sponsors and Collaborators
Hospital de Clinicas de Porto Alegre
Investigators
Principal Investigator: Pedro Dall'Ago, Professor Hospital de Clinicas de Porto Alegre
  More Information

No publications provided

Responsible Party: Pedro Dall'Ago, Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier: NCT00950937     History of Changes
Other Study ID Numbers: 06067
Study First Received: February 16, 2009
Results First Received: February 16, 2009
Last Updated: August 4, 2009
Health Authority: Brazil: National Committee of Ethics in Research

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

ClinicalTrials.gov processed this record on May 16, 2013